Lv3
378 积分 2023-03-01 加入
Unveiling the intra-tumor fate of trastuzumab deruxtecan in a xenograft model to support its mechanism of action
34分钟前
待确认
Glucocorticoid-induced osteoporosis: pathophysiology and therapy
1天前
已完结
Evolving Strategies for Target Selection for Antibody-Drug Conjugates
5天前
已完结
A pre-clinical quantitative model predicts the pharmacokinetics/pharmacodynamics of an anti-BDCA2 monoclonal antibody in humans
6天前
已完结
Design and Development of Glucocorticoid Receptor Modulators as Immunology Antibody–Drug Conjugate Payloads
6天前
已完结
Discovery of ABBV-3373, an Anti-TNF Glucocorticoid Receptor Modulator Immunology Antibody Drug Conjugate
6天前
已完结
DB-2304, a Duality Immune Modulating Antibody‒Drug Conjugate (DIMAC) targeting BDCA2, displays strong potency in the suppression of pDC functions
6天前
已完结
Bulumtatug Fuvedotin (BFv, 9MW2821), a next-generation Nectin-4 targeting antibody–drug conjugate, in patients with advanced solid tumors: a first-in-human, open-label, multicenter, phase I/II study
10天前
已完结
Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study
14天前
已完结
Inhibiting TROP2 in advanced non-small-cell lung cancer with sacituzumab govitecan, datopotamab deruxtecan, and sacituzumab tirumotecan: similarities and differences
16天前
已完结
皖公网安备34019202002308
